Cabaletta Bio, Inc.
No SEC Form 4 filings for $CABA in the last 30 days.
See all $CABA insider activity →Investing.com reports Cabaletta Bio (CABA) shares fell about 1.6% after Q2 2026 results. Net loss was $(0.73) per share, down 30% year over year. Cash was about $225.1M, expected to fund operations only into mid-2027. The update included Phase 1/2 data and a new CMC partner, plus an SEC Form 8-K.
Cabaletta Bio, Inc. (CABA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 caba-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update Registrational RESET-Myositis ® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel Juvenile m
Cabaletta Bio, Inc. (CABA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001759138 --12-31 false 0001759138 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): J
Over the past 7 days, alphai's AI scored 2 news stories mentioning CABA (Cabaletta Bio, Inc.). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.
Recent CABA coverage spans financial news, earnings and corporate actions.
The earnings print and near-term cash runway likely dominate the tape, increasing dilution risk concerns despite positive Phase 1/2 and CMO expansion.
The filing reinforces a near-to-medium term clinical and regulatory roadmap (BLA timing, cohort starts) plus manufacturing capacity expansion, which can re-rate risk for rese-cel development.
Share-authorization increase can facilitate future equity issuance/dilution; near-term trading may hinge on whether markets expect financing needs.
Early-stage autoimmune CAR-T data plus a stated path to BLA and commercial supply agreement can re-rate risk sentiment, but remains pre-approval and small-cohort.
The filing of a Form 8-K suggests an important corporate event that could influence investor perception and stock performance.
alphai scores every news story that mentions CABA with an AI model for sentiment and relevance, and aggregates insider trades from Cabaletta Bio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Investing.com reports Cabaletta Bio (CABA) shares fell about 1.6% after Q2 2026 results. Net loss was $(0.73) per share, down 30% year over year. Cash was about $225.1M, expected to fund operations only into mid-2027. The update included Phase 1/2 data and a new CMC partner, plus an SEC Form 8-K.
4 min readCabaletta Bio, Inc. (CABA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 caba-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update Registrational RESET-Myositis ® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel Juvenile m
7 min readCabaletta Bio, Inc. (CABA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001759138 --12-31 false 0001759138 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): J
2 min readCabaletta Bio (NASDAQ:CABA) reported positive early clinical and translational data from the first four patients in the lowest-dose cohort of preconditioning-free (PC-free) rese-cel, an investigational autologous CAR T therapy for autoimmune diseases, and manufacturing/translational results from the first two autoimmune patients treated using the Cellares Cell Shuttle platform. The company said higher doses may be needed without preconditioning and that 50% showed drug-free responses for six mon
4 min readThis report indicates that Cabaletta Bio has filed a Form 8-K which is a current report used to announce events that shareholders should know about. Without further details, the specific nature of the event cannot be determined. Investors should review the full filing for more information.
2 min readCabaletta Bio Inc.'s stock surged by roughly 32% after reporting early positive results from a small cell-therapy trial and announcing a $150 million stock sale that included Eli Lilly as an investor. The company's new funds, combined with existing cash, are expected to cover operating and capital needs into mid-2027. Cabaletta is also preparing to present fresh data from its rese-cel trial at the American Society of Gene & Cell Therapy meeting on May 14.
4 min readCellares announced that the first two patients have been dosed with Cabaletta Bio's investigational CAR T cell therapy, rese-cel, manufactured using Cellares' automated Cell Shuttle platform. This milestone demonstrates the feasibility of scalable, automated manufacturing for autologous cell therapies, aiming for high capacity, flexible supply, and reduced costs. Cabaletta Bio's CEO, Steven Nichtberger, highlighted this a significant achievement towards minimizing capital investment and lowering the cost of goods for their therapeutic programs.
3 min readHere is how AtriCure (ATRC) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.
2 min read- All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS responses with no immunomodulators -
2 min read- Complete B cell depletion, rapid reduction in autoantibodies and near-complete resolution of clinical symptoms in two of three refractory patients; all three patients remained off immunomodulators since infusion and are off or tapering steroids as of the data cut-off -
2 min read
